Company: NDRA
Filing Date: 2025-11-26
Form Type: 424B4
Source: 0001213900-25-115097
Chunk: 12

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-26
Form: 424B4
Chunk 12
---
 “Where You Can Find Additional Information.“ Please also read carefully the above section “Special Note Regarding Forward-Looking Statements.“

Risks Related to this Offering

You may experience future dilution
as a result of future equity offerings.

In order to raise additional
capital, we may at any time, including during the pendency of this offering, offer additional shares of our common stock or other securities
convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We
may sell shares of our common stock or other securities in any other offering at a price per share that is less than the price per share
paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing
stockholders. The price per share at which we sell shares of our common stock, or securities convertible or exchangeable into common
stock, in future transactions may be higher or lower than the price per share paid by investors in this offering.

Because we do not anticipate paying
any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.

We plan to reinvest all of
our earnings, to the extent we have earnings, in order to continue to develop our products, to market our products, to cover operating
costs and to otherwise become and remain competitive. We do not plan to pay any cash dividends with respect to our securities in the
foreseeable future. Any future determination to pay cash dividends will be at the discretion of our board of directors and will depend
on applicable law and then-existing conditions, including our financial condition, operating results, contractual restrictions, capital
requirements, business prospects and other factors our board of directors may deem relevant. See “Dividend Policy.” As a
result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.

Our stock price and trading volume has fluctuated in the past, has recently been volatile and may be volatile in the future for reasons unrelated to our operating performance or prospects, and as a result, investors in our common stock could incur substantial losses.

Our stock price has fluctuated
in the past, has recently been volatile and may be volatile in the future. From January 1, 2025 through September 30, 2025, intra-day
trading prices of shares of our common stock on the Nasdaq Capital Market fluctuated from